Skip to main content

Treatment Clinical Trials for Recurrent Brain Neoplasm

Review the recurrent brain neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 43

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Status: Active
Location: 41 locations
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Status: Active
Location: 34 locations
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Status: Active
Location: 19 locations
Tocilizumab for the Treatment of Progressive or Recurrent Pediatric Adamantinomatous Craniopharyngioma
Status: Active
Location: 6 locations
Binimetinib for the Treatment of Pediatric Progressive or Recurrent Adamantinomatous Craniopharyngioma
Status: Active
Location: 4 locations
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Status: Active
Location: 8 locations
Donor Immune Cells (Ex Vivo Expanded Natural Killer Cells) for the Treatment of Recurrent or Progressive Malignant Brain Tumors in Children and Young Adults
Status: Active
Location: 9 locations
Digoxin for the Treatment of Pediatric and Young Adult Patients with Relapsed Non-SHH, Non-WNT Medulloblastoma
Status: Active
Location: 8 locations
ACT001 for the treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive, Refractory, or Recurrent DIPG or H3K27-Altered High Grade Gliomas
Status: Active
Location: 6 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 5 locations
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Location: 6 locations
Chemotherapy and CAR-T Cell Immunotherapy (Brain Tumor‐Specific Immune Cells) for the Treatment of IL13Ralpha2 Positive Recurrent or Refractory Brain Tumors or Newly Diagnosed DIPG/DMG
Status: Active
Location: 3 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Location: 2 locations
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: 2 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
Atovaquone Alone or Combined with Radiation for the Treatment of Children with Malignant Brain Tumors
Status: Active
Location: 2 locations
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Laser Interstitial Thermal Therapy or Surgery and Adjuvant Reirradiation for the Treatment of Patients with Recurrent Brain Metastases, LaSAR BeaM Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Metformin for the Treatment of Recurrent or Progressive Posterior Fossa Group A Ependymoma, PNOC041 Trial
Status: Active
Location: University of California San Francisco, San Francisco, California
Lerapolturev versus Lomustine for the Treatment of Recurrent GBM
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland